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Abbreviations 
 
LTFU - loss to follow up 
UHID - university hospital for infectious disease 
AIDS - acquired immunodeficiency syndrome 
HIV - human immunodeficiency virus 
ART - antiretroviral therapy 
VL - viral load 
CD4 - CD4 positive T helper cells 
MSM - men who have sex with men 
IVDU - intravenous drug users 
IRR - incidence rate ratio 
GIP - gubitak iz praćenja 
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Summary: 
Title: LOSS TO FOLLOW-UP IN HIV INFECTED PERSONS IN CROATIA IN PERIOD 
2006-2017 
Author: Sandra Hrnčić 
 
In Croatia healthcare is public and antiretroviral therapy (ART) is covered by health 
insurance. The following study investigates the possible risk factors influencing rates of 
LTFU. Database of patients followed in the University hospital for infectious disease 
(UHIC) Zagreb, the centre holding data for all HIV infected persons followed in the 
period between 1.7.2006. and 1.7.2016. in Croatia was used. We extracted the data 
from the electronic database at UHID and included into study all Croatian residents ​≥​ 18 
years old, with at least one year of follow-up and at least 2 visits. LTFU was defined as 
present if there was no visit for 12 months or the patient had no ART supplies for more 
than 3 months. The follow-up ended on december 31, 2017 or earlier if the patient died, 
moved or interrupted care. ​Associations between factors and LTFU rates were 
quantified using repeated measures Poisson regression. Of 1091 patients, 240 (22%) 
had a total of 336 episodes of LTFU. The rate of LTFU was 4.23 (95% CI, 3.80–4.70) 
per 100 person-years. Multivariable predictors of UHCI included viral load (VL) >200 
copies/ml (Incidence Rate Ratio (IRR)) 1.77 (95% CI:1.42–2.20), age (per 10 years) 
IRR 0.84 (95% CI: 0.76–0.93), prior UHCI (per episode) IRR 3.49 (95% CI: 3.04–4.00), 
calendar year (2006–2009 vs 2010–2016) IRR 1.50 (95% CI 1.20–1.87) and time under 
follow-up (per year) IRR 1.14 (95% CI 1.11–1.18). Of 240 patients with at least one 
UHCI 16 (6.7%) died whereas of 851 without an LTFU 44 (5.2%) died (P=0.369). 
Measured < 200 cell/mm​3 ​had no definite correlation with LTFU rates when comparing 
bivariate and multivariate analysis ​. At the last visit at UHID, of 240 patients with an 
LTFU 127 (52.9%) had reentered care, 16 had died, 8 moved and 89 (37.1%) had an 
LTFU. 
 
Keywords: HIV, loss to follow up, viral load 
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Sažetak 
 
Naslov: GUBITAK OSOBA ZARAŽENIH HIV-OM IZ PRAĆENJA U REPUBLICI 
HRVATSKOJ U RAZDOBLJU OD 2006. DO 2017. GODINE 
Autorica: Sandra Hrnčić 
 
U Hrvatskoj zdravstvena zaštita je javna i antiretroviralna terapija (ART) je pokrivena 
zdravstvenim osiguranjem. Ovo istraživanje preispituje moguće faktore rizika koji utiću 
na stope gubitka iz praćenja (GIP). Korištena je baza podataka pacijenata praćenih 
Sveućilišnoj bolnici za infektivne bolesti klinike u Zagrebu, centra koji sadrži podatke 
svih osoba zaraženih HIV-om praćenih u Hrvatskoj u periodu između 1.7.2006. I 
1.7.2016.Izvadili smo podatke iz elektronske baze podataka klinike za infektivne bolesti 
i uključili u istraživanje sve stanovnike Republike Hrvatske koji imaju ​≥ 18 godina, sa 
barem godinu dana praćenja i barem 2 posjeta. ​Gubitak iz njege je definiran kao 
postojeći kada nema niti jednog posjeta klinici 12 mjeseci ili pacijent nije imao ART 
zalihe za više od 3 mjeseca. Praćenje je završilo 31. Prosinca, 2017. Ili ranije ako je 
pacijent umro, preselio se ili prekinuo sa njegom. Poveznice između faktora i stopa GIP 
su kvantificirane koristeći Poissonovu regresiju ponovljenih mjerenja.Od 1091 
pacijenata ​, 240 (22%) je iskusilo ukupno 336 episode GIP. Stopa GIP je bila 4.23 (95% 
CI, 3.80–4.70) po 100 osoba-godina. Multivarijatni predkazivači GIP uključivali su 
koncentraciju virusa >200 kopija/ml (Incidence Rate Ratio (IRR)) 1.77 (95% 
CI:1.42–2.20), dob (per 10 years) IRR 0.84 (95% CI: 0.76–0.93), prijašnje GIC (po 
epizodi) IRR 3.49 (95% CI: 3.04–4.00), kalendarske godine (2006–2009 vs 2010–2016) 
IRR 1.50 (95% CI 1.20–1.87) i vrijeme praćenja (po godini) IRR 1.14 (95% CI 
1.11–1.18). Od 240 pacijenata sa barem jednim GIP 16 (6.7%) je umrlo dok od 851 bez 
GIP 44 (5.2%) je umrlo (P=0.369). Izmjereni CD4​ < 200 cell/mm​3 ​ nisu imali korelaciju 
sa stopama GIP kada su bivarijatna i multivarijantna analiza uspoređene. Pri zadnjem 
posjetu bolnici, od 240 osoba sa GIP, 127 (52.9%) je ponovno ušlo u praćenje, 16 je 
umrlo, 8 se odselilo i ​89 (37.1%) je imalo GIP.  
 
Ključne riječi: HIV, gubitak iz njege, virusno opterećenje 
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Preface/introduction 
 
 
Since its discovery in 1983. ​1​ human immunodeficiency virus (HIV) has become one of 
the major disease burdens globally. With its transmission through sexual and blood 
contact it has grown into a global pandemic. 36,7 million people were reportedly living 
with HIV in the year 2016. ​2​ of which 1,433 were of croatian resident citizens​3​. Of those 
reportedly infected 1,8 million cases were newly diagnosed that year of which 106 
persons were Croatian resident citizens. This information  makes it appear as a rising 
trend in this particular country as 5% of the individuals globally were infected this year, 
while this percentage in croatian relations was 7% placing it above the standard.  
 
Antiretroviral therapy was introduced in 1996.​4​ and improved the quality of life and 
prognosis for those suffering from the progression of the disease by reducing the viral 
load. Availability of these medication programmes reduced the probability of 
transmission and made HIV infection preventable. In a country with a public health 
system such as Croatia where antiretroviral therapy (ART) is completely covered by 
health insurance and available in several different regiments it is surprising to find that 
the rates of infection continued to rise in the present time.  
 
HIV is one of the less common chronic infections found in the communicable disease 
group and therefore available for analysis in a long term cohort study. A method of loss 
to follow up is appropriate in observing the compliance of patients to therapy and 
investigating the factors responsible for the rise in the trend of infection and patient 
dropping out of care.  
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Loss to follow up is dropping patients out of care after being in care for a period of time. 
The following study is made to advance the knowledge about factors leading to loss to 
follow up in order to decrease its incidence as well as the disease spread.  
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Hypothesis 
 
 
The hypothesis of this study is that LTFU is correlated to lower CD4 count, higher viral 
load and higher mortality rates. Also, it is hypothesized that it is related to time under 
treatment, age, gender, mode of transmission, location of residence, and coinfection 
with hepatitis B, and hepatitis C.  
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Objectives 
 
The objective of this study is to examine aspects influencing LTFU. The following 
factors have been examined: age, gender, place of residence, CD4 count, VL, mode of 
exposure, time under follow-up, previous episode of LTFU and coinfection with either 
HCV or HBV. 
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Methods 
 
Study setting 
 
Persons included in the study are patients followed in the referent centre in Zagreb 
University hospital for infectious diseases (Fran Mihaljević), Croatia. This is the the sole 
centre holding data for all HIV infected persons in Croatia.  
 
Patients 
 
Data of HIV infected persons in Croatia collected in the period between 1.1.2006. and 
1.7.2016. was included in the study, however the censor date for the data collection was 
31.12.2017. Those individuals reported to have moved were excluded from the study as 
well as patients under 18 years of age due to ethical reasons. Visit was defined as 
patient seen in outpatient department or to have picked up prescription medication, 
hospitalizations were not included in this definition. Patients needed at least 2 visits or 
drug prescription within the same year to be considered being in care, therefore patients 
with only one visit were not considered to be in care to begin with. Patients needed to 
be followed at least one year to be considered in care. Those who moved would 
assumed to have moved 1 day after last visit. Patients with HIV type 2 infection were 
removed from the study.  
 
 
Data collection 
 
All the data was extracted from the hospital database. Information was recorded by the 
hospital staff at the time of the patient admission and visits. Due to the human error 
factor data had to be cleaned prior to processing. This included removing persons with 
11 
incorrect visit dates or times of death as well as those with variable values well out of 
range of normal limits.  
 
 
LTFU definition 
 
ART drug prescriptions at UHID in Zagreb can range in their duration from one month, 
two month, three month, six month and even twelve month prescription. Persons living 
outside of the capital where the centre is situated, those working seasonal jobs who are 
away for long periods of time and those with stable laboratory findings can benefit from 
this flexibility. ​For the patients who died LTFU was defined as being over 90 days prior 
to the last visit.  
 
Considering the variation in drug prescription LTFU had to be defined differently for 
different groups of patients but it revolved around the patient having no visit or contact 
for over 3 months. For those whose ART prescriptions are issued for up to 9 months 
LTFU is defined as not being renewed for 12 months since the date of the issuing. 
Therefore the patient is potentially not in contact for 3 months since the last issuing. For 
the patients whose prescriptions are issued for 10, 11 or 12 months LTFU is defined as 
not being renewed for 3 months after the last issuing meaning the patient is out of 
contact from 1 up to 15 months. ​The last date of patient inclusion was made 1.7.2016. 
so that the newly received patients had an opportunity to be included into the study and 
experience LTFU. For patients who died LTFU was defined as last visit or prescription 
being over 3 months prior to date of death.  
 
Factors/variables measured 
 
During the course of this study specific variables were analyzed in the context of 
measuring LTFU. Of the general variables age, gender, area of residence and mode of 
HIV transmissions were considered in measuring LTFU. ​Age was divided into several 
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groups, the first being ages 18-29, second 29-39, third 39-49 and fourth 50 and above 
years of age. ​Calendar year trends were noted and patients were divided into two 
groups to compare the trend of LTFU in the first half and second half of the study 
period. The main modalities focused on during measuring were viral load and CD4 
count. Viral load was defined as when it was ​>200 copies/ml. CD4 count was divided 
into groups of greater or even than 500 ​cell/mm​3​, equal to 200-499 cell/mm​3​ or less than 
200 cell/mm ​3​.​ These variables were compared in participants who had LTFU to those 
who did not have LTFU. We used first, last and lowest CD4 measurement. Infectious 
diseases other than HIV infections compared in this study were hepatitis C, hepatitis B 
and syphilis. Lastly, portion of patients who died and obtained AIDS were noted.  
 
Study design and analysis 
 
Loss the follow-up in HIV infected persons was analyzed in a form of a retrospective 
cohort study. ​Cohort censor date was 31.12.2017. Data was analyzed using statistical 
analysis software (SAS). Crude rates were calculated and Poisson regression analysis 
was made, with general estimating equations methods. Bivariate analysis was 
performed, the number of LTFU episodes was calculated for each variable, stating 
whether the LTFU occured (yes), was absent (no) and the corresponding p value was 
calculated. Incidence rate ratios were calculated for each variable to assess the 
probability that the variable is connected to LTFU. Bivariate and multivariate analysis 
was made.  
 
Ethical statement 
 
Patients in care are given a consent form for their data to be analysed in studies. This 
was part of the Croatian Science Foundation project (project number IP-2014-09-446, 
principal investigator dr. sc. prof. J. Begovac) for which ethical approval was given by 
UHID and University of Zagreb School of Medicine.  
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Patients that were under the age of 18 at the time of the first visit were excluded from 
the study due to ethical reasons. 
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Results 
 
After the criteria was applied, according to crude calculation, the number of patients 
known to have had HIV in the period of 2006.-2016. included in the study was 1091 of 
which 1045 ​(95.8%) received ART. In this population median follow up was 7.5 years 
(Q1-Q3, 4.1–11.1). 
Of 1091, ​60 (5.5%)​ persons had died during the duration of the study, of which 42 had 
died within 90 days of the last visit and were therefore not considered out of care. 
240 (22%) persons included in the study experienced LTFU with a total of 336 
episodes. Frequency of LTFU episodes was calculated as well as frequency per 
number of episodes in a single patient. The results were shown in ​ ​table 1​.  
Of those who experienced LTFU 127 (52.9%) reentered care, 16 (6.7%) had died and 8 
had moved. Exactly 89 (37.1%) of those patients experienced LTFU after reentering 
care. The total follow up was added to be 7950.9 years and after incidence rate ratio 
(IRR) calculation it was found that the rate of follow up was 4.23 (95% CI 3.80 - 4.70) at 
100 person years. 
 
In the examined population 969 (88.8%) were males, whose IRR of LTFU were 4.23 
(95% CI: 3.56 - 4.50). 433 (39.7) live inside of city of Zagreb county with a IRR of 3.76 
(95% CI: 3.12 - 4.53), while outside of Zagreb were 658 (60.3%) with IRR 4.48 (95% CI: 
3.93 - 5.10). ​Age was divided into different groups as explained earlier. The ​median age 
in sample population was 43.9 (Q137.0 - Q352.7), while the median age of patients with 
LTFU was, 41.5 (Q34.4 - Q49.8).  Majority of the patients (n748 (68.6%)) had men who 
have sex with men (MSM) as the main route of HIV transmission. 
 
According to bivariate analysis factors correlated to the increased rates of LTFU were 
age (0.7 (CI 95%: 0.62-0.78), year of first diagnosis (1.36 (95% CI: 1.13-1.63), CD4 
count at inclusion ≥ 500 cells/mm3 (1.12 (95% CI: 1.07-1.17), time dependant viral load 
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≥ 200 copies/ml (4.39 (95% CI: 1.04-1.92), time under follow up (1.07(95% CI: 
1.04-1.09) and previous LTFU (3.56 (95% CI: 3.19-3.98).  
 
After the multivariate analysis was performed, when analyzing age, ​the highest IRR 
associated was associated with the youngest group with those 18-29 years of age and it 
was 2.07 (95% CI: 1.83 - 2.30). Intravenous drug users (IVDU) had the highest 
incidence of loss to follow up, but when it came to regression analysis MSM group had 
the incidence rate of 1.40 (95% CI: 1.26 - 1.54) while the non MSM patients together 
had an IRR of 1.50 (95% CI: 1.33 - 1.67). 
 
After the p value calculation the lowest was found in younger age, last VL 
measurement, first CD4 measurement and last CD4 measurement. Last VL 
measurement with a detectable count (> ​200 copies/ml)​, while both CD4 measurements 
were related to low counts (<200 cells/mm ​3​). 
 
Infectious diseases other than HIV infections compared in this study were hepatitis C 
and hepatitis B none of which showed correlation to higher rates of LTFU. 
Portion of patients who died and obtained AIDS were noted (n=293). However 
statistically the connection to increased LTFU was not established.  
 
The aim of comparing the analyses of bivariate and multivariate analysis was to 
eliminate possible confounding factors. The variables highly correlated to rates of LTFU 
in both sets were younger age, detectable viral load at first measurement, time under 
follow up, and previous episodes of LTFU. 
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Table 1:​ ​LTFU frequencies using univariate analysis 
 
Cumulative 
LTFU Frequency Percent 
Cumulative 
Frequency 
Cumulative 
Percent 
0 853 78.04 853 78.04 
1 170 15.55 1023 93.60 
2 52 4.76 1075 98.35 
3 12 1.10 1087 99.45 
4 4 0.37 1091 99.82 
5 2 0.18 1093 100.00 
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 Table 2. Dichotomous table listing main variables and calculated p values 
 
 LTFU yes/no  
Variables 
Total 
N=1091(%) No N=851(%) Yes N=240(%) 
P 
Value 
Risk    0.168 ​† 
IVDU 7 (0.6) 7 (0.8) 0 (0.0)  
MSM 748 (68.6) 593 (69.7) 155 (64.6)  
Mother to child 2 (0.2) 1 (0.1) 1 (0.4)  
IVDU 41 (3.8) 27 (3.2) 14 (5.8)  
hetero 263 (24.1) 200 (23.5) 63 (26.3)  
unknown 30 (2.7) 23 (2.7) 7 (2.9)  
Risk1    0.133 
MSM 748 (68.6) 593 (69.7) 155 (64.6)  
Non MSM 343 (31.4) 258 (30.3) 85 (35.4)  
Gender    0.153 
female 122 (11.2) 89 (10.5) 33 (13.8)  
male 969 (88.8) 762 (89.5) 207 (86.3)  
Age    <.001 
Median (q25 - 
q75) 
43.9 (37.0 - 
52.7) 
44.6 (37.8 - 
53.5) 
41.5 (34.4 - 49.8)  
CD4 last    <.001 
Median (q25 - 
q75) 
609.0 (437.0 - 
805.0) 
626.0 (468.0 - 
840.0) 
522.5 (341.5 - 
705.5) 
 
Minimal CD4    0.136 
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Median (q25 - 
q75) 
199.0 (60.0 - 
335.0) 
195.0 (61.0 - 
326.0) 
218.0 (57.0 - 
372.5) 
 
Min CD4    0.915 
Median (q25 - 
q75) 
266.0 (116.0 - 
401.0) 
264.0 (129.0 - 
396.0) 
273.0 (86.5 - 
453.0) 
 
Live in Zagreb    0.067 
No 658 (60.3) 501 (58.9) 157 (65.4)  
Yes 433 (39.7) 350 (41.1) 83 (34.6)  
Died    0.369 
alive 1031 (94.5) 807 (94.8) 224 (93.3)  
died 60 (5.5) 44 (5.2) 16 (6.7)  
AIDS    0.287 
Had AIDS 293 (26.9) 235 (27.6) 58 (24.2)  
No AIDS 798 (73.1) 616 (72.4) 182 (75.8)  
Last VL count    <.001 
Greater or 
even to  200 
82 (7.5) 20 (2.4) 62 (25.8)  
Less than 200 1009 (92.5) 831 (97.6) 178 (74.2)  
Last CD4 
count 
   <.001 
200 to 499 317 (29.1) 230 (27.0) 87 (36.3)  
ge 500 722 (66.2) 592 (69.6) 130 (54.2)  
lt 200 52 (4.8) 29 (3.4) 23 (9.6)  
First VL count    0.897 
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ge 200 833 (76.4) 649 (76.3) 184 (76.7)  
lt 200 258 (23.6) 202 (23.7) 56 (23.3)  
First CD4 
count 
   <.001 
200 to 499 497 (45.6) 389 (45.7) 108 (45.0)  
ge 500 303 (27.8) 209 (24.6) 94 (39.2)  
lt 200 291 (26.7) 253 (29.7) 38 (15.8)  
Hepatitis B    0.560 
No 1028 (94.2) 800 (94.0) 228 (95.0)  
Yes 63 (5.8) 51 (6.0) 12 (5.0)  
Hepatitis C    0.047 
No 1025 (94.0) 806 (94.7) 219 (91.3)  
Yes 66 (6.0) 45 (5.3) 21 (8.8)  
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Table 3: Bivariate and multivariate analysis results 
 
 Bivariate Multivariate 
Variable IRR (95% CI) P-values IRR (95% CI) 
P-value
s 
Gender     
  Male 1 0.043   
  Female 1.46 (1.01–2.11)    
Age  < 0.001  < 0.001 
per 10 years older 0.7 (0.62–0.78)   0.84 (0.76–0.93)  
Exposure     
 MSM 0.89 (0.69–1.15) 0.372   
 non-MSM 1  
 
 
 
HCV (ever)  0.028   
  No 0.63 (0.41–0.95)    
  Yes 1    
HBsAg (ever)  0.302   
  No 1.31 (0.78–2.2)    
  Yes 1    
Year HIV positive  0.715   
 < 2010 1.05 (0.81–1.35)    
 ge 2010 1    
Year inclusion  < 0.001   
 < 2010 1.36 (1.14–1.63)  1.50 (1.20–1.87)  
 ge 2010 1    
CD4 cell count at 
inclusion 
 < 0.001   
 per 100 cells 1.12 (1.07–1.17)    
21 
CD4 cell count at 
inclusion 
    
  ≥ 500 2.56 (1.78–3.7) < 0.001 0.79 (0.59-1.08) 0.118 
  200-499 cells/mm ​3 1.66 (1.16–2.37) 0.005 0.82 (0.62-1.08) 0.152 
  < 200 cells/mm ​3 1  1  
VL at inclusion, 
copies/ml 
 0.028   
  ≥ 200 1.41 (1.04–1.92)    
  <200 1    
Viral load time 
dependent, copies/ml 
 < 0.001  < 0.001 
  ≥ 200 4.39 (3.65–5.28)  1.77 (1.42–2.20)  
  <200 1    
Time under follow-up  < 0.001  < 0.001 
  per 1 additional year 1.07 (1.04–1.09)  1.14 (1.11–1.18)  
Episode of previous 
LTFU 
 < 0.001  < 0.001 
  Yes 3.56 (3.19–3.98)  3.49 (3.04–4.00)  
  No 1    
Living in Zagreb  0.383   
  No 1.12 (0.87–1.46)    
  Yes 1    
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Discussion 
From the result given the rate of LTFU in Croatia was ​4.23 (95% CI, 3.80–4.70) per 100 
person-years. In comparison, in an observational study performed in Europe the result 
was ​3.72 (95% CI:3.58-3.86)  per 100 person-years of follow-up​5​ which brings us close 
to the European average . 
In answer to the hypothesis the results have indeed shown that rates of LTFU were 
correlated to detectable VL in both bivariate (IRR 1.41 (95% CI: 1.04–1.92))  and 
multivariate (IRR ​1.77 (95% CI: 1.42–2.20))​ analysis. ​In an Australian observational 
study it was ​1.19 (95% CI 1.14–1.23), which was also highly correlated to the LTFU 
rates making it also a strong predictor of LTFU.  
Higher CD4 count was correlated to higher rates of LTFU in the bivariate analysis 
which would indicate direct correlation, whereas in the multivariate it was correlated to 
lower CD4 counts. This would indicate that the variable possibly has no correlation to 
the LTFU rate and is therefore a suppressor factor. When variable previous LTFU 
episode was removed from the multivariate analysis the CD4 count was correlating to 
the bivariate analysis which a point that deserves further analysis. Mortality rates were 
not correlated with the rates of LTFU in either of the analyses.  
When observing figure 1 taken from Croatian department of public health it is obvious 
that the death rates continued to remain relatively constant throughout the years further 
emphasizing the lack of the correlation between LTFU and increased mortality together 
with the high p value (p = ​0.369​). While the EuroSIDA trial didn’t record death rates, the 
Australian surveillance study ​11​ revealed similar results as Croatia. They compared the 
population against the death register and came to the finding that 10.5% of the patients 
who died were linked to LTFU whereas in Croatia this percentage was 6.7%.  
 
Time under follow-up was directly correlated to increased rates of LTFU in both 
bivariate (IRR 1.07 (95% CI: 1.04–1.09)) and multivariate (IRR 1.14 (95% CI: 
23 
1.11–1.18)) analyses. This may be explained by the fact that it is more likely to 
experience a longer period of absence from care in the longer time under care.  
Previous episode of LTFU was also highly correlated to increased rates of repeated 
LTFU episode with high IRR results, for bivariate analysis being 3.56 (95% CI: 
3.19–3.98) and multivariate analysis being ​3.49 (95% CI: 3.04–4.00). Considering the 
high degree of correlation between the two analyses it may be interpreted as resulting 
from the variable itself as much as from the sum of other variables.  
 
When observing the trend in LTFU in those infected by HIV it is easily noted by both the 
frequency and incidence rate that the amount of people experiencing LTFU decreased 
in the second half of the interval chosen (figure 2). However, the total amount of 
patients increased in those years as well as can be seen from the Croatian department 
of public health epidemiological analysis (figure 1). This decrease may be due to the 
free HIV screening standardized on the European Union level and introduced in 2013.​9 
together with treatment promotion as can be observed from the graph.  
 
24 
 
Figure 1: HIV infection, death and AIDS trends in Croatia between years 1985. And 2016. 
Taken from Croatian Department of Public Health​10 
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Figure 2: LTFU number of episodes in two different year intervals 
 
When it comes to age in the EuroSIDA ​12​trial the older patients were more likely to have 
lower rates of ltfu as it shows that those 10 years older on average had an IRR of ​0.85  
(95% CI: ​0.80–0.89​) which was also the case in the Croatian trial where the age group 
of 18-29 years old had the highest rates ​2.07 (95% CI: 1.83 - 2.30).​ Mode of 
transmission in the same study had increased IRR in IVDU (IRR 2.16 CI: 1.84 - 2.53 
p<0.001), whereas in a Croatia MSM patients had the lowest LTFU rates.  
 
Considering the major findings of this cohort, all of the above mentioned studies showed 
similar results. In the Australian study​13​ LTFU in patients with low CD4 had a med​ian of 
480 ( ​Q1-Q3, ​320–665), in Guinea-Bissau​14​ it was 210 (Q1-Q3, 97–391), in EuroSIDA​15 
study 261 (Q1-Q3, 120-420) while in this study the CD4 count at the last measurement 
had a ​median of 522.5 (Q1-Q3, 341.5–705.5) per mm​3​. This would strongly connect the 
finding of LTFU correlating to a lower CD4 count, however as it was aforementioned, 
this was not the case when the variables were analysed as set in this study. 
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Some of the things that might have influenced the results were the definition variety of 
LTFU, especially when comparing it to appropriate studies from other areas. More so, 
there is a potential for bias from provider of health care considering prescriptions that 
might have influenced patients and therefore results. In a study performed in Zambia ​16​ it 
was shown that longer drug prescription de-burdened the clinics and corresponded to 
lower rates of LTFU.  
Furthermore, the only centre for treatment is in the capital, around 520 km from furthest 
city of the country which, accessibility might have had to do with compliance of a certain 
population but it was not correlated to definite lower rates of LTFU. It is encouraging to 
see how the organisation of the care is still providing adequate coverage for the surface 
area of the country.  
Lastly, when it comes to definition itself, as it was stated before LTFU was defined in a 
very specific parameters. In a study done in South Africa, Asia and South America by 
comparing specificity and sensitivity of definitions it was established that LTFU defined 
as absence of 180 days had the lowest rate of misclassification. However, in the study 
performed in Zagreb that was difficult to execute considering the difference in patient 
visits since the centre is situated so far from the furthest point of the country.  
 
Considering the rates calculated and the amount of people to have experienced LTFU 
according to the established definition (22%) according to certain studies that is above 
the limit of validity. However, when compared to similar studies in the HIV population in 
different countries Croatian population was not on the upper side especially if 
comparing rates. A study in Guinea-Bissau ​6​showed the highest rate of LTFU of 51.1 
per person years , a study in Nigeria showed a rate of 12.3 while the European standard 
from a EuroSIDA​7​ study involving ​12 304 patients from across Europe ​showed a LTFU 
incidence of 3.72 (95% CI: 3.58-3.86) but the results did vary from 0.67 to 13.35 
according to the region. Australian ​8​ population was at the very bottom with 1.63 (95% 
CI: 1.45 - 1.84). Croatia therefore cuts closest to the European standard with 4.23 (95% 
CI 3.80 - 4.70).  
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Some variables covered by other studies that would be useful to investigate in the future 
are prior episodes, time between visits and BMI. Lower BMI of patients in particular was 
investigated in the Guinea-Bissau research ​17​ and found to be correlated to the LTFU 
perhaps due to the fact that those with other chronic comorbidities might frequent to the 
physician more or due to possible high AIDS rates as anorexia is part of the symptoms 
and the study hasn’t monitored mortality.  
 
In further investigation I would introduce a control as well as examine whether the 
prescription influences the follow up of the patient for the intervals longer than 6 months. 
Considering the variety in side effects the patients might have lower compliance for 
some regiments considering that they do not feel ill when they are not medicated but 
this is a matter that would require a questionnaire. Likewise, it would be useful to 
examine whether the patients with longer prescription of the medications are more 
compliant to take them since they are given more independence by the physician which 
was the case in a study done in Zambia​18​ or, on the other hand, the patients with shorter 
prescription would make sure to take them regularly as they will be controlled at the 
clinic. In addition, considering distance was connected to the compliance of the patient it 
would be interesting to see which region in particular had higher LTFU rates and 
whether it was indeed proportional to how far away the patient lives from the centre. 
Another interesting parameter to examine would be patient education, investigating 
whether the patients are perhaps not understanding the gravity of their illness and the 
simplicity of the treatment. It would be informative to compare LTFU in different levels of 
education as well as depending on how well their physician educated them on the 
disease.  
 
 
 
 
 
28 
 
Conclusions 
 
LTFU has been statistically correlated to detectable VL, time under care and previous 
episode of LTFU but it hasn’t influenced the patient mortality nor has it been definitely 
connected to higher CD4 counts at inclusion. Younger age, male gender, distance from 
the health center, as well as IVDU was connected to greater rates of LTFU but they 
didn’t seem to provide definite answers.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
29 
Acknowledgements 
 
I would like to thank my thesis mentor Dr. Josip Begovac for inspiring me to pursue this path 
and supporting me in finishing the graduation paper. I would also like to thank my friends and 
family for their infinite patience and support, and Freddie Mercury for lifting me up when I was at 
my lowest.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
30 
References 
 
 
1. UpToDate. [cited 2018Jun18]. Available from: 
https://www.uptodate.com/contents/the-natural-history-and-clinical-features-of-hiv
-infection-in-adults-and-adolescents 
2. HIV/AIDS [Internet]. World Health Organization. World Health Organization; 
[cited 2018Jun18]. Available from: 
http://www.who.int/mediacentre/factsheets/fs360/en/ 
3. Epidemiologija HIV infekcije i AIDS-a u Hrvatskoj [Internet]. ​Hrvatski​. [cited 
2018Jun18]. Available from: 
https://www.hzjz.hr/sluzba-epidemiologija-zarazne-bolesti/epidemiologija-hiv-infe
kcije-i-aids-a-u-hrvatskoj/ 
4. Early loss of HIV-infected patients on potent antiretroviral therapy programmes in 
lower-income countries [Internet]. World Health Organization. World Health 
Organization; 2011 [cited 2018Jun18]. Available from: 
http://www.who.int/bulletin/volumes/86/7/07-044248/en/ 
5. Sullivan AK, Sperle I, Raben D, Amato-Gauci AJ, Lundgren JD, Yazdanpanah Y, 
et al. HIV testing in Europe: Evaluating the impact, added value, relevance and 
usability of the European Centre for Disease Prevention and Control (ECDC)’s 
2010 HIV testing guidance. Eurosurveillance. 2017;22(48). 
6. Hønge BL, Jespersen S, Nordentoft PB, Medina C, da D, da ZJ, et al. Loss to 
follow-up occurs at all stages in the diagnostic and follow-up period among 
HIV-infected patients in Guinea-Bissau: a 7-year retrospective cohort study. 
[Internet]. Advances in pediatrics. U.S. National Library of Medicine; 2013 [cited 
2018Jun18]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/24163204 
7. Mocroft A, Kirk O, Aldins P, Chies A, Blaxhult A, Chentsova N, et al. Loss to 
follow-up in an international, multicentre observational study. [Internet]. Advances 
31 
in pediatrics. U.S. National Library of Medicine; 2008 [cited 2018Jun18]. 
Available from: https://www.ncbi.nlm.nih.gov/pubmed/18400074 
8. McManus H, Petoumenos K, Brown K, Baker D, Russell D, Read T, et al. 
[Internet]. Advances in pediatrics. U.S. National Library of Medicine; 2015 [cited 
2018Jun18]. Available from: 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4424189/ 
9. Sullivan AK, Sperle I, Raben D, Amato-Gauci AJ, Lundgren JD, Yazdanpanah Y, 
et al. HIV testing in Europe: Evaluating the impact, added value, relevance and 
usability of the European Centre for Disease Prevention and Control (ECDC)’s 
2010 HIV testing guidance. Eurosurveillance. 2017;22(48). 
10.Epidemiologija HIV infekcije i AIDS-a u Hrvatskoj [Internet]. ​Hrvatski​. [cited 
2018Jun18]. Available from: 
https://www.hzjz.hr/sluzba-epidemiologija-zarazne-bolesti/epidemiologija-hiv-infe
kcije-i-aids-a-u-hrvatskoj/ 
11.Mcmanus H, Petoumenos K, Brown K, Baker D, Russell D, Read T, et al. Loss to 
follow-up in the Australian HIV Observational Database. Antiviral Therapy. 
2014;20(7):731–41. 
12.Mocroft A, Kirk O, Aldins P, Chies A, Blaxhult A, Chentsova N, et al. Loss to 
follow-up in an international, multicentre observational study. HIV Medicine. 
2008;9(5):261–9. 
13.Mcmanus H, Petoumenos K, Brown K, Baker D, Russell D, Read T, et al. Loss to 
follow-up in the Australian HIV Observational Database. Antiviral Therapy. 
2014;20(7):731–41. 
14.Hønge BL, Jespersen S, Nordentoft PB, Medina C, Silva DD, Silva ZJD, et al. 
Loss to follow-up occurs at all stages in the diagnostic and follow-up period 
among HIV-infected patients in Guinea-Bissau: a 7-year retrospective cohort 
study. BMJ Open. 2013;3(10). 
32 
15.Mocroft A, Kirk O, Aldins P, Chies A, Blaxhult A, Chentsova N, et al. Loss to 
follow-up in an international, multicentre observational study. HIV Medicine. 
2008;9(5):261–9. 
16.Mody, Aaloke, Roy, Monika, Thea, Holmes, et al. Improved Retention With 
6-Month Clinic Return Intervals for Stable Human Immunodeficiency 
Virus-Infected Patients in Zambia | Clinical Infectious Diseases | Oxford 
Academic [Internet]. PLOS Biology. Public Library of Science; 2017 [cited 
2018Jun27]. Available from: https://doi.org/10.1093/cid/cix756 
17.Hønge BL, Jespersen S, Nordentoft PB, Medina C, Silva DD, Silva ZJD, et al. 
Loss to follow-up occurs at all stages in the diagnostic and follow-up period 
among HIV-infected patients in Guinea-Bissau: a 7-year retrospective cohort 
study. BMJ Open. 2013;3(10). 
18.Mody, Aaloke, Roy, Monika, Thea, Holmes, et al. Improved Retention With 
6-Month Clinic Return Intervals for Stable Human Immunodeficiency 
Virus-Infected Patients in Zambia | Clinical Infectious Diseases | Oxford 
Academic [Internet]. PLOS Biology. Public Library of Science; 2017 [cited 
2018Jun27]. Available from: https://doi.org/10.1093/cid/cix756 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
33 
 
Biography  
 
Sandra Hrnčić is a 6th year medical student finishing the Medical Studies in English 
program of the University of Zagreb, Croatia. She has shown interest in the area of 
medicine since early age, a love that has deepened after enrolling into the medical 
faculty. Her true passion has shown to become infectious disease and tropical medicine 
after completing the course, leading her to enrol into a MSF preparatory course at the 
University of Copenhagen the following summer. After finishing the studies she plans to 
pursue a specialisation in the field and hopefully do an internship in southeast Asia.  
 
